Skip to main content

Use of Chinese herbal medicine therapies in comprehensive hospitals in central China: A parallel survey in cancer patients and clinicians

Journal of Huazhong University of Science and Technology [Medical Sciences] volume 35, pages 808–814 (2015)Cite this article

Abstract

Chinese herbal medicine (CHM), as the largest application category of traditional Chinese medicine (TCM), is widely accepted among cancer patients in China. Herbal slice (HS) and Chinese patent drug (CPD) are commonly used CHM in China. This study aimed to investigate the utilization of CHM among clinicians and cancer patients in central China. Five hundred and twenty-five patients and 165 clinicians in 35 comprehensive hospitals in central China were asked to complete an anonymous questionnaire that was designed to evaluate the use of CHM. The results showed that 90.74% clinicians and 72.24% cancer patients used CHM during cancer treatment. The educational backgrounds of the clinicians and the age, education level, annual income, and cancer stage of the cancer patients were related to use of CHM. More than 90% clinicians and cancer patients had used CPD. Comparatively, the percentage of HS use was 10% lower than that of CPD use among clinicians and cancer patients. More clinicians preferred to use CHM after surgery than cancer patients did (20.41% vs. 5.37%). Enhancing physical fitness and improving performance status were regarded as the most potential effect of CHM on cancer treatment (85.71% among clinicians and 94.07% among cancer patients), in comparison with directly killing tumor cells (24.49% among clinicians and 31.36% among patients). As for refusal reasons, imprecise efficacy was the unanimous (100%) reason for clinicians’ rejection of CHM, and 95.58% patients objected to using CHM also for this reason. Furthermore, the side effects of CHM were more concerned by clinicians than by patients (33.33% vs. 15.81%). In conclusion, our survey revealed that CHM was popularly accepted by clinicians and cancer patients in central China. The reasons of use and rejection of CHM were different between clinicians and cancer patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Cui Y, Shu XO, Gao Y, et al. Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Res Treat, 2004,85(3):263–270

    Article  PubMed  Google Scholar 

  2. Chen Z, Gu K, Zheng Y, et al. The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med, 2008,14(8): 1049–1055

    Article  PubMed  Google Scholar 

  3. McQuade JL, Meng Z, Chen Z, et al. Utilization of and attitudes towards traditional Chinese medicine therapies in a Chinese cancer hospital: A survey of patients and physicians. Evid Based Complement Alternat Med, 2012,2012:504–507

    Article  Google Scholar 

  4. Ernst E, Cassileth BR. The prevalence of complementary/ alternative medicine in cancer: a systematic review. Cancer, 1998,83(4):777–782

    Article  CAS  PubMed  Google Scholar 

  5. Horneber M, Bueschel G, Dennert G, et al. How many cancer patients use complementary and alternative medicine: a systematic review and meta-analysis. Integr Cancer Ther, 2012,11(3):187–203

    Article  PubMed  Google Scholar 

  6. Teng L, Jin K, He K, et al. Use of complementary and alternative medicine by cancer patients at Zhejiang University Teaching Hospital Zhuji Hospital, China. Afr J Tradit Complement Altern Med (Chinese), 2010,7(4): 322–330

    Google Scholar 

  7. Pu CY, Lan VM, Lan CF, et al. The determinants of traditional Chinese medicine and acupuncture utilization for cancer patients with simultaneous conventional treatment. Eur J Cancer Care, 2008,17(4):340–349

    Article  Google Scholar 

  8. Liu TG, Xiong SQ, Yan Y, et al. Use of Chinese herb medicine in cancer patients: a survey in southwestern china. Evid Based Complement Alternat Med, 2012, 2012: Article ID:769042,7 pages,2012

    Google Scholar 

  9. Harmsworth K, Lewith GT. Attitudes to traditional Chinese medicine amongst Western trained doctors in the People’s Republic of China. Soc Sci Med, 2001,52(1): 149–153

    Article  CAS  PubMed  Google Scholar 

  10. Chen M. Year Book of Health in the People’s Republic of China, Beijing: RenminWeisheng Pressing, 1997.

  11. Lee RT, Hlubocky FJ, Hu JJ, et al. An international pilot study of oncology physicians’ opinions and practices on complementary and alternative medicine (CAM). Integr Cancer Ther, 2008,7(2):70–75

    Article  PubMed  Google Scholar 

  12. Lu P, Liang QD, Li R, et al. Effect of traditional Chinese medicine on survival and quality of life in patients with esophageal carcinoma after esophagectomy. Chin J Integr Med (Chinese), 2006,12(3):175–179

    Article  Google Scholar 

  13. Jeong JS, Ryu BH, Kim JS, et al. Bojungikki-tang for cancer-related fatigue: a pilot randomized clinical trial. Integr Cancer Ther, 2010,9(4):331–338

    Article  CAS  PubMed  Google Scholar 

  14. Piao BK, Wang YX, Xie GR, et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res (Chinese), 2004,24(1):303–309

    CAS  Google Scholar 

  15. Loo WT, Jin LJ, Chow LW, et al. Rhodiola algida improves chemotherapy-induced oral mucositis in breast cancer patients. Expert Opin Investig Drugs, 2010,19 (Suppl 1):S91–S100

    Article  CAS  PubMed  Google Scholar 

  16. Dai AW, Li ZY, Wang LH, et al. Effect of Yangyin Humo decoction on oral mucomembranous reaction to radiotherapy. Chin J Integr Med (Chinese), 2009,15(4): 303–306

    Article  Google Scholar 

  17. Li GY, Yu XM, Zhang HW, et al. Haishengsu as an adjunct therapy to conventional chemotherapy in patients with non-small cell lung cancer: a pilot randomized and placebo-controlled clinical trial. Complement Ther Med, 2009,17(2):51–55

    Article  PubMed  Google Scholar 

  18. Zheng Y. The therapeutic effects of rehmannia oral liquid for the syndrome of heat accumulation with Yin consumption in esophagus cancer patients undergoing radiotherapy—a report of 60 cases. J Tradit Chin Med, 2007,27(4):248–254

    PubMed  Google Scholar 

  19. Guo Z, Jia X, Liu JP, et al. Herbal medicines for advanced colorectal cancer. Cochrane Database Syst Rev, 2012,5:CD004653

    PubMed  Google Scholar 

  20. Liu YX, Jiang SJ, Kuang TH, et al. Treatment with yiqibushen koufuye combined with chemotherapy for preventing postoperative metastasis of stomach cancer—a clinical observation of 28 cases. J Tradit Chin Med (Chinese), 2009,29(4):263–267

    Article  CAS  Google Scholar 

  21. Zhang L, Wu C, Zhang Y, et al. Efficacy comparison of traditional Chinese medicine LQ versus gemcitabine in a mouse model of pancreatic cancer. J Cell Biochem, 2013,114(9):2131–2137

    Article  CAS  PubMed  Google Scholar 

  22. Tsou YA, Chen KC, Lin HC, et al. Uroporphyrinogen decarboxylase as a potential target for specific components of traditional Chinese medicine: a virtual screening and molecular dynamics study. PLoS One, 2012,7(11):e50087

    Article  Google Scholar 

  23. Bao YX, Wong CK, Leung SF, et al. Clinical studies of immunomodulatory activities of Yunzhi-Danshen in patients with nasopharyngeal carcinoma. J Altern Complement Med, 2006,12(8):771–776

    Article  PubMed  Google Scholar 

  24. Guo HY, Cai Y, Yang XM, et al. Randomized phase II trial on mitomycin-C/cisplatin +/-KLT in heavily pretreated advanced breast cancer. Am J Chin Med, 2008,36(4):665–674

    Article  CAS  PubMed  Google Scholar 

  25. Swisher EM, Cohn DE, Goff BA, et al. Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol, 2002,84(3):363–367

    Article  PubMed  Google Scholar 

  26. Yang YY, Dong Z, Zhu SB, et al. Reevaluation on adverse reaction monitoring and safety of CMMPP of Chongqing from 2005 to 2011. Zhongguo Zhong Yao Za Zhi (Chinese), 2012,37(23):3659–3663

    Google Scholar 

  27. Critchley JA, Zhang Y, Suthisisang CC, et al. Alternative therapies and medical science: designing clinical trials of alternative/complementary medicines is evidence-based traditional Chinese medicine attainable. J Clin Pharmacol, 2000,40(5):462–467

    Article  CAS  PubMed  Google Scholar 

  28. Tian JH, Liu LS, Shi ZM, et al. A randomized controlled pilot trial of “Feiji Recipe” on quality of life of non-small cell lung cancer patients. Am J Chin Med, 2010,38(1): 15–25

    Article  PubMed  Google Scholar 

  29. Wu WY, Long SQ, Zhang HB, et al. Improvement of quality of life with Shenfu injection in non-small cell lung cancer patients treated with gemcitabine plus cisplatin regimen. Chin J Integr Med (Chinese), 2006,12(1): 50–54

    Article  Google Scholar 

  30. Xu L, Li H, Xu Z, et al. Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients. BMC Complement Altern Med, 2012,12:112

    PubMed Central  Article  PubMed  Google Scholar 

  31. Yu Y, Lang Q, Chen Z, et al. The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study. Cancer, 2009,115(22):5132–5138

    Article  PubMed  Google Scholar 

  32. Zhou LY, Shan ZZ, You JL. Clinical observation on treatment of colonic cancer with combined treatment of chemotherapy and Chinese herbal medicine. Chin J Integr Med (Chinese), 2009,15(2):107–111

    Article  Google Scholar 

  33. Xu ZY, Jin CJ, Zhou CC, et al. Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy. J Cancer Res Clin Oncol, 2011,137(7):1117–1122

    Article  PubMed  Google Scholar 

  34. Guo H, Liu JX, Xu L, et al. Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy. Integr Cancer Ther, 2011,10(2):127–137

    Article  PubMed  Google Scholar 

  35. Chen YZ, Li ZD, Gao F, et al. Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer. Chin J Integr Med (Chinese), 2009,15(6):415–419

    Article  CAS  Google Scholar 

  36. Zhang Y, Lin HS. Tumor stem cells may be the final target of traditional Chinese medicine in preventing cancer recurrence and metastasis. Zhongguo Zhong Xi Yi Jie He Za Zhi (Chinese), 2009,29(50):461–463

    CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Integrated Traditional Chinese Medicine and Western Medicine, Huazhong University of Science and Technology, Wuhan, 430030, China

    Gang Chen, Ting-ting Qiao, Hao Ding, Chen-xi Li, Hui-ling Zheng, Xiao-ling Chen & Shao-ming Hu

  2. Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    Shi-ying Yu

Authors
  1. Gang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ting-ting Qiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hao Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chen-xi Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hui-ling Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiao-ling Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shao-ming Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shi-ying Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shi-ying Yu.

Additional information

This project was supported by Hubei Provincial Health Department Research Fund Project of China (No. 2012Z-Y10).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen, G., Qiao, Tt., Ding, H. et al. Use of Chinese herbal medicine therapies in comprehensive hospitals in central China: A parallel survey in cancer patients and clinicians. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 35, 808–814 (2015). https://doi.org/10.1007/s11596-015-1511-5

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-015-1511-5

Keywords

  • Traditional Chinese Medicine
  • Chinese Herbal Medicine
  • Kill Tumor Cell
  • Religious Faith
  • Integrative Medicine